Reportlinker Adds Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Apr 21, 2011, 06:06 ET
NEW YORK, April 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global Traumatic Brain Injury Therapeutics market. The report identifies the key trends shaping and driving the global Traumatic Brain Injury Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Traumatic Brain Injury Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Traumatic Brain Injury Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Traumatic Brain Injury Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Traumatic Brain Injury Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Traumatic Brain Injury Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Traumatic Brain Injury Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Traumatic Brain Injury Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Traumatic Brain Injury Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Traumatic Brain Injury Therapeutics market landscape? – Identify, understand and capitalize.
Table of Contents
1 Table of contents
1 Table of contents 2
1.1 List of Tables 4
1.2 List of Figures 5
2 TBI Therapeutics: Introduction 6
2.1 Disease Overview 6
2.2 Epidemiology 9
2.3 Etiology 9
2.4 Signs and Symptoms 10
2.5 Diagnosis 10
2.6 Treatment and management Pattern 12
2.7 GlobalData Pipeline Report Guidance 14
3 TBI Therapeutics: Market Characterization 15
3.1 Overview 15
3.2 TBI Therapeutics Market Size (2005–2010) – Global 15
3.3 TBI Therapeutics Market Forecast (2010–2017) – Global 16
3.4 TBI Therapeutics Market Size (2005–2010) – The US 17
3.5 TBI Therapeutics Market Forecast (2010–2017) – The US 18
3.6 TBI Therapeutics Market Size (2005–2010) – France 19
3.7 TBI Therapeutics Market Forecast (2010–2017) – France 20
3.8 TBI Therapeutics Market Size (2005–2010) – Germany 21
3.9 TBI Therapeutics Market Forecast (2010-2017) – Germany 22
3.10 TBI Therapeutics Market Size (2005–2010) – Italy 23
3.11 TBI Therapeutics Market Forecast (2010–2017) – Italy 24
3.12 TBI Therapeutics Market Size (2005–2010) – Spain 25
3.13 TBI Therapeutics Market Forecast (2010–2017) – Spain 26
3.14 TBI Therapeutics Market Size (2005–2010) – The UK 27
3.15 TBI Therapeutics Market Forecast (2010–2017) – The UK 28
3.16 TBI Therapeutics Market Size (2005–2010) – Japan 29
3.17 TBI Therapeutics Market Forecast (2010–2017) – Japan 30
3.18 Drivers and Barriers for TBI Therapeutics Market 31
3.18.1 Drivers for the TBI Therapeutics Market 31
3.18.2 Barriers for the TBI Therapeutics Market 31
3.19 Opportunity and Unmet Need Analysis 32
3.19.1 Opportunity and Unmet Need in the TBI Market, 2010 32
3.20 Key Takeaway 32
4 TBI Therapeutics: Competitive Assessment 33
4.1 Overview 33
4.2 Strategic Competitor Assessment 33
4.3 Product Profile for the Major Marketed Products in the TBI Therapeutics 34
4.3.1 NovoSeven 34
4.3.2 Mannitol 35
4.4 Key Takeaway 35
5 TBI Therapeutics: Pipeline Assessment 36
5.1 Overview 36
5.2 Strategic Pipeline Assessment 36
5.3 TBI Therapeutics Pipeline – Pipeline by Phases of Development 36
5.3.1 TBI Therapeutics – Phase III Pipeline 37
5.3.2 TBI Therapeutics –Phase II Pipeline 37
5.3.3 TBI Therapeutics –Phase I Pipeline 38
5.3.4 TBI Therapeutics – Preclinical Phase 38
5.3.5 TBI Therapeutics – Discovery Pipeline 38
5.4 Technology Trends Analytic Framework 39
5.5 TBI Therapeutics – Clinical Pipeline by Mechanism of Action 41
5.6 TBI Therapeutics – Promising Drugs under Clinical Development 42
5.7 Molecule Profiling for Promising Drugs under Clinical development 42
5.7.1 BHR-100 42
5.7.2 NHOO1 43
5.8 Key Takeaway 43
6 TBI Therapeutics: Clinical Trials Mapping 44
6.1 Clinical Trials by Region/ Country 44
6.2 Clinical Trials by Phase 45
6.3 Clinical Trials by Trial Status 46
6.4 Top 10 companies participating in Therapeutics Clinical Trials 47
6.5 Prominent Sponsors 48
7 TBI Therapeutics: Strategic Assessment 50
7.1 Key Events Impacting the Future Market 50
7.2 Implications for Future Market Competition 51
8 TBI Therapeutics: Future Players 52
8.1 Introduction 52
8.2 Company Profiles 52
8.2.1 BHR Pharma, LLC 52
8.2.2 Vasopharm GmbH 53
8.2.3 NeuroHealing Pharmaceuticals Inc. 54
9 TBI Therapeutics: Licensing and Partnership Deals 55
10 TBI Therapeutics: Appendix 56
10.1 Market Definitions 56
10.2 Abbreviations 56
10.3 Research Methodology 57
10.3.1 Coverage 57
10.3.2 Secondary Research 57
10.3.3 Forecasting 58
10.3.4 Primary Research 61
10.3.5 Expert Panel Validation 61
10.4 Contact Us 61
10.5 Disclaimer 61
10.6 Bibliography 62
List of Tables
1.1 List of Tables
Table 1: Common Types Of TBI 8
Table 2: Management Of TBI Based on Severity of Injury 11
Table 3: TBI Therapeutics Market, Global, Revenue, ($m), 2005–2010 15
Table 4: TBI Therapeutics Market, Global, Forecast ($m), 2010–2017 16
Table 5: TBI Therapeutics Market, The US, Revenue ($m), 2005–2010 17
Table 6: TBI Therapeutics Market, The US, Forecast ($m), 2010–2017 18
Table 7: TBI Therapeutics Market, France, Revenue ($m), 2005–2010 19
Table 8: TBI Therapeutics Market, France, Forecasts ($m), 2010–2017 20
Table 9: TBI Therapeutics Market, Germany, Revenue ($m), 2005–2010 21
Table 10: TBI Therapeutics Market, Germany, Forecast ($m), 2010–2017 22
Table 11: TBI Therapeutics Market, Italy, Revenue ($m), 2005–2010 23
Table 12: TBI Therapeutics Market, Italy, Forecast ($m), 2010–2017 24
Table 13: TBI Therapeutics Market, Spain, Revenue ($m), 2005–2010 25
Table 14: TBI Therapeutics Market, Spain, Forecast ($m), 2010–2017 26
Table 15: TBI Therapeutics Market, The UK, Revenue ($m), 2005–2010 27
Table 16: TBI Therapeutics Market, The UK, Forecast ($m), 2010–2017 28
Table 17: TBI Therapeutics Market, Japan, Revenue ($m), 2005–2010 29
Table 18: TBI Therapeutics Market, Japan, Forecast ($m), 2010–2017 30
Table 19: TBI Therapeutics – Phase III Clinical Pipeline, 2011 37
Table 20: TBI Therapeutics – Phase II Clinical Pipeline, 2011 37
Table 21: TBI Therapeutics – Phase I Clinical Pipeline, 2011 38
Table 22: TBI Therapeutics – Preclinical Pipeline, 2011 38
Table 23: TBI Therapeutics – Discovery Pipeline, 2011 38
Table 24: TBI Therapeutics – Most Promising Drugs Under Clinical Development, 2011 42
Table 25: TBI Therapeutics Market, Clinical Trials by Region/ Country 44
Table 26: TBI Therapeutics Market, Clinical Trials by Phase, 2011 45
Table 27: TBI Therapeutics Market, Clinical Trials by Trial Status, 2011 46
Table 28: TBI Therapeutics Market, Clinical Trials by Top 10 Companies Participating in Therapeutics Clinical Trials, 2011 47
Table 29: TBI Therapeutics Market – Clinical Trials by Overall Sponsors, 2011 48
Table 30: TBI Therapeutics Market – Clinical Trials by Prominent Sponsors, 2011 49
Table 31: BHR Pharma – CNS Pipeline Products, 2011 53
Table 32: Vasopharm GmbH – CNS Pipeline Products, 2011 53
Table 33: Vasopharm GmbH, Deals, 2009 53
Table 34: NeuroHealing Pharmaceuticals – CNS Pipeline Products, 2011 54
Table 35: TBI Therapeutics Market, Global, Deals, 2004-2006 55
List of Figures
1.2 List of Figures
Figure 1: TBI Classification on the Basis of Severity Of Injury 6
Figure 2: Effects of TBI 7
Figure 3: TBI Therapeutics Market – Causes 9
Figure 4: TBI Continuum of Care 12
Figure 5: TBI Therapeutics Market, Global, Revenue ($m), 2005–2010 15
Figure 6: TBI Therapeutics Market, Global, Forecast ($bn), 2010–2017 16
Figure 7: TBI Therapeutics Market, The US, Revenue ($m), 2005–2010 17
Figure 8: TBI Therapeutics Market, The US, Forecast ($m), 2010–2017 18
Figure 9: TBI Therapeutics Market, France, Revenue ($m), 2005–2010 19
Figure 10: TBI Therapeutics Market, France, Forecast ($m), 2010–2017 20
Figure 11: TBI Therapeutics Market, Germany, Revenue ($m), 2005–2010 21
Figure 12: TBI Therapeutics Market, Germany, Forecast ($m), 2010–2017 22
Figure 13: TBI Therapeutics Market, Italy, Revenue ($m), 2005–2010 23
Figure 14: TBI Therapeutics Market, Italy, Forecast ($m), 2010–2017 24
Figure 15: TBI Therapeutics Market, Spain, Revenue ($m), 2005–2010 25
Figure 16: TBI Therapeutics Market, Spain, Forecast ($m), 2010–2017 26
Figure 17: TBI Therapeutics Market, The UK, Revenue ($m), 2005–2010 27
Figure 18: TBI Therapeutics Market, The UK, Forecast ($m), 2010–2017 28
Figure 19: TBI Therapeutics Market, Japan, Revenue ($m), 2005–2010 29
Figure 20: TBI Therapeutics Market, Japan, Forecast ($m), 2010–2017 30
Figure 21: Opportunity and Unmet Need in the TBI Therapeutics Market, 2010 32
Figure 22: Strategic Competitor Assessment of the Marketed Products for TBI, 2011 33
Figure 23: TBI Therapeutics Pipeline by Phase of Development, 2011 36
Figure 24: Technology Trends Analytic Framework of the TBI Therapeutics Pipeline, 2011 39
Figure 25: Technology Trends Analytic Framework of the TBI Therapeutics pipeline- Description, 2011 40
Figure 26: TBI Therapeutics, Clinical Pipeline by Mechanism of Action, 2011 41
Figure 27: TBI Therapeutics Market – Clinical Trials by Region/Country, 2011 44
Figure 28: TBI Therapeutics Market – Clinical Pipeline by Phase, 2011 45
Figure 29: TBI Therapeutics Market – Clinical Trials by Trial Status, 2011 46
Figure 30: TBI Therapeutics Market – Clinical Trials by Top 10 Companies Participating in Therapeutics Clinical Trials, 2011 47
Figure 31: TBI Therapeutics Market – Clinical Trials by Overall Sponsors, 2011 48
Figure 32: TBI Therapeutics Market – Clinical Trials by Prominent Sponsors, 2011 49
Figure 33: TBI Therapeutics, Global, Key Events Impacting the Future Market 50
Figure 34: Implications for Future Market Competition in the TBI Therapeutics Market, 2011 51
Figure 35: TBI Therapeutics Market – Clinical Pipeline by Company, 2011 52
Figure 36: GlobalData Market Forecasting Model 60
To order this report:
: Traumatic Brain Injury (TBI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article